ALK and non-small cell lung carcinoma: Impressively, the three-year survival rates for patients with a PD-L1 greater than or equal to 90% treated with PD-1 monotherapy are close to the three-year OS rates of patients with EGFR-mutant or ALK-positive NSCLC receiving osimertinib or the first-generation ALK inhibitor crizotinib, respectively, which range from 50% to 60%.13